General Information of Drug Transporter (DT)
DT ID DTD0028 Transporter Info
Gene Name SLC47A2
Transporter Name Multidrug and toxin extrusion protein 2
Gene ID
146802
UniProt ID
Q86VL8
Exogenous Factors (drugs, dietary constituents, etc.) Modulating DT Activity (EFMDA)
Exogenous Factor Quinine Approved Drug
DT Modulation Quinine inhibits the transportation of 1-methyl-4-phenylpyridinium by SLC47A2 (IC50 = 6.4 microM) [1]
Affected Drug/Substrate 1-methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-MATE2
DT Modulation Quinine inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 23.1 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Cimetidine Approved Drug
DT Modulation Cimetidine inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 7.3 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
DT Modulation Cimetidine inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 2.1 microM) [3]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor DX-619 Discontinued Drug
DT Modulation DX-619 inhibits the transportation of Creatinine by SLC47A2 (Ki = 0.1 microM) [4]
Affected Drug/Substrate Creatinine Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Famotidine Approved Drug
DT Modulation Famotidine inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 9.7 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Pramipexole Approved Drug
DT Modulation Pramipexole inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 24.1 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Ranitidine Approved Drug
DT Modulation Ranitidine inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 25 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Verapamil Approved Drug
DT Modulation Verapamil inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 32.1 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Diltiazem Approved Drug
DT Modulation Diltiazem inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 117 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Talipexole Drug in Phase 4 Trial
DT Modulation Talipexole inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 119.5 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Procainamide Approved Drug
DT Modulation Procainamide inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 178.1 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Imipramine Approved Drug
DT Modulation Imipramine inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 182.9 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Chlorpheniramine Approved Drug
DT Modulation Chlorpheniramine inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 191.2 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Diphenhydramine Approved Drug
DT Modulation Diphenhydramine inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 266.5 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Desipramine Approved Drug
DT Modulation Desipramine inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 283 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Disopyramide Approved Drug
DT Modulation Disopyramide inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 291.6 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Cetirizine Approved Drug
DT Modulation Cetirizine inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 817.6 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Amantadine Approved Drug
DT Modulation Amantadine inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 1167 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Metformin Approved Drug
DT Modulation Metformin inhibits the transportation of Tetraethylammonium by SLC47A2 (Ki = 6515.7 microM) [2]
Affected Drug/Substrate Tetraethylammonium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Cigarette smoke condensate Natural Product
DT Modulation Cigarette smoke condensate inhibits the activity of SLC47A2 (IC50 = 61.4 microM) [5]
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Carvedilol Approved Drug
DT Modulation Carvedilol inhibits the activity of SLC47A2 (IC50 = 202 microM) [6]
Cell System Human embryonic kidney 293 cells (HEK293)-MATE2
Exogenous Factor Cobicistat Approved Drug
DT Modulation Cobicistat inhibits the activity of SLC47A2 (IC50 = 3.2 microM) [7]
Exogenous Factor Ritonavir Approved Drug
DT Modulation Ritonavir inhibits the activity of SLC47A2 (IC50 = 90 microM) [7]
Exogenous Factor Green tea Natural Product
DT Modulation Green tea inhibits the transportation of Metformin by SLC47A2 [8]
Affected Drug/Substrate Metformin Modulation Type Inhibition
Cell System Human enterocyte-like 2 cell (Caco-2)-MATE2
Exogenous Factor Itraconazole Approved Drug
DT Modulation Itraconazole inhibits the activity of SLC47A2 [9]
Exogenous Factor Ketoconazole Approved Drug
DT Modulation Ketoconazole inhibits the activity of SLC47A2 [9]
Exogenous Factor Plazomicin Approved Drug
DT Modulation Plazomicin inhibits the activity of SLC47A2 [10]
Exogenous Factor Tetraethylammonium Investigative Drug
DT Modulation Tetraethylammonium modulates the activity of SLC47A2 [11]
References
1 Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther. 2012 Jun;341(3):743-55.
2 Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther. 2009 Apr;329(1):185-91.
3 Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 2012 Feb;340(2):393-403.
4 Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther. 2011 Jan;89(1):81-8.
5 Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017 Oct;44:27-35.
6 Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. Pharm Res. 2018 Sep 6;35(11):204.
7 No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted With Ritonavir or Cobicistat. J Pharm Sci. 2019 Apr 26. pii: S0022-3549(19)30289-8.
8 Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. PLoS One. 2015 Oct 1;10(10):e0139370.
9 Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. Drug Metab Dispos. 2016 Mar;44(3):453-9.
10 No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Jan 3.
11 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.